Interstitial lung diseases (ILDs) are a group of diffuse parenchymal lung disorders that are classified according to different clinical, radiological and histopathological features. Interstitial lung disease can be primary or it can be due to a secondary cause, such as an underlying connective tissue disease (CTD). Rheumatoid arthritis (RA) is the most common CTD, and ILD can be found in a quarter of RA patients. Interstitial lung disease has a significant impact on RA patients in terms of their burden of disease and quality of life. Despite this it remains largely understudied and pathogenesis is unclear. Newer imaging techniques include ultrasound and 18F-FDG PET/CT. Therapeutics that show promise include mycophenolate mofetil and rituximab. Paradoxically, some of the agents that are good in treating articular manifestations in RA patients can result in the worsening or development of ILD.
INTRODUCTION
Interstitial lung diseases (ILDs) may occur as idiopathic interstitial pneumonias (IIPs) or in association with connective tissue diseases (CTDs) 1, 2 . Interstitial lung disease may manifest prior, during or even years after the diagnosis of the underlying CTD is made 3 . Connective tissue diseases most commonly associated with ILD include systemic sclerosis (SSc), RA, polymyositis and dermatomyositis, mixed connective tissue disease (MCTD), primary Sjogren's syndrome and undifferentiated CTD (UCTD) [4] [5] [6] [7] [8] [9] . Serologic evaluation for autoantibodies, detailed search for clinical signs and symptoms of underlying CTDs, radiologic and histopathological features are important clues to aid in the diagnosis of the underlying CTD. This is important as unlike IIPs, ILD associated with CTDs are often of the nonspecific interstitial pneumonia (NSIP) subtype, are responsive to anti-inflammatory therapy and generally carry a better prognosis 10 .
EPIDEMIOLOGY
Rheumatoid arthritis (RA) is associated with extraarticular manifestations in around 40% of patients, and ILD is often found in up to 25% of patients 11 . It is important to note that ILD might be the only presenting manifestation of systemic disease in up to 15% of patients 12, 13 . The first description of pulmonary involvement in RA was by Ellman and Ball, who described three cases of RA with extensive pulmonary disease in 1948 14 . Men are more affected and lifetime risk of developing ILD in RA patients is about 10% 15 . Risk factors for developing ILD in RA include male gender 16 , smoking 17 , rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) positivity [18] [19] [20] , a long disease duration of RA and the presence of extra-articular features of RA 21 . Interstitial lung disease is recognised as an important risk factor of mortality and morbidity in RA, and mean survival from diagnosis is about three years 15, 22 . The incidence of ILD associated with RA appears to be rising and it has been shown to account for almost 6% of all RA deaths 23 .
Patients with ILD often are breathless and have a chronic cough. Smoking is important to elicit in the history 39 , as it is one of the predictors of development of ILD and is usually associated with a usual interstitial pneumonia (UIP) pattern of lung disease on histology 40 , which has a poorer prognosis 41 . To establish a diagnosis of RA-ILD, it would be important to ask for history of joint pains and early morning stiffness, as well as look for other extra-articular manifestations of RA, for example rheumatoid nodules. Digital clubbing, central cyanosis and bilateral fine end-inspiratory crepitations heard on auscultation are other features suggestive of ILD. Of interest is that finger clubbing is not common in patients with RA-ILD as compared to patients with IPF, occurring in less than 20% of patients, even at equivalent levels of pulmonary dysfunction and hypoxia 42 . Pulmonary hypertension is an important complication of ILD to look out for, and patients can have a loud pulmonary component of the second heart sound and a right parasternal heave, or present with signs and symptoms of right heart failure, such as ascites, raised jugular venous pressure and bilateral pitting pedal oedema.
INVESTIGATIONS FOR RA-ILD
Investigations useful in aiding the diagnosis of RA-ILD would include the presence of RF and anti-CCP, the presence of fine reticulate shadowing bibasally on chest x-ray, a restrictive pattern on lung function test and decreased transfer factor (also known as diffusing capacity for carbon monoxide). A transfer factor of <54% of the predicted value was specific for disease progression 43 . High resolution computed tomography (HRCT) of the chest is more sensitive and specific in the diagnosis of ILD 44 . Furthermore, HRCT allows for the extent of disease to be assessed and a radiological pattern of disease can be inferred. The extent of disease is categorised as limited if less than 20% of the lung parenchyma is affected, and as extensive otherwise 45 . Four major radiographic patterns of lung disease have been identified in RA patients, a UIP-like pattern of involvement with bilateral subpleural reticulation and honeycombing; a NSIP-like pattern with predominant ground-glass opacities; inflammatory airway disease pattern with centrilobular branching lines and bronchial dilatation; and an organising pneumonia-like pattern with patchy areas of consolidation 46 . Studies have shown good correlation between the histopathologic pattern found on surgical lung biopsies and the radiographic patterns seen on HRCT
PATHOGENESIS OF ILD
Pathogenesis of ILD in CTDs is still unclear, in particular RA. Anti-CCP has been detected in bronchoalveolar lavages 24 , and patients with anti-CCP without arthritis have gone on to develop ILD 25 . This has led to the postulation that citrullination in the lungs leads to the generation of anti-CCP antibodies, which then promotes lung abnormalities in patients with RA, especially in smokers 26 . Smoking might increase peptidylarginine deaminase (PAD) 2 expression and cause citrullination in the lungs, thus causing human leukocyte antigen (HLA)-DR (shared epitope)-restricted immune reactions 24, 27 .
Much of the information is gathered from ILD associated with SSc and idiopathic pulmonary fibrosis (IPF). Whereas older models of lung fibrosis featured an atypical wound healing response in response to a single injury, the more recent concept involves bouts of repeated injury to structural cells (i.e. alveolar epithelium or endothelium), causing macrophage-driven responses, resulting in fibroblast activation and accumulation of extracellular matrix, with eventual scarring of lung parenchyma 28 . Possible mediators of fibrosis include caspase-3 29 and lysophosphatide acid, 30 which have been found to be increased in the lungs of SSc-ILD patients. The innate immunity may also have a role in fibrosis, as Toll-like receptor (TLR) 4 tenascin C has been detected in SSc-ILD lungs 31 . Monocytes may also be implicated in the pathogenesis of ILD, and levels of interleukin 18 (IL-18) predict clinical decline in SSc-ILD 32, 33 . CD19+ B cells have a role in the development of fibrosis, as depletion of CD19+ B cells ameliorates skin and lung fibrosis in animal models 34 . Decreased levels of CD4+CD25+FoxP3+ regulatory T cells (Tregs) 35 and increased levels of Th17 cells have also been noted in SSc-ILD patients 36 . Autoimmunity too has a role in the pathogenesis of ILD, and the strongest relationship is seen with autoantibodies against topoisomerase-1, which induces lung fibrosis in mice via IL-6 dependent mechanisms 37 .
CLINICAL MANIFESTATIONS OF RA-ILD
All RA patients should be screened at baseline for the presence of RA-ILD. This is because ILD can occur in 10% of patients prior to the development of arthritis, and synchronously in 5% of patients with RA 38 . Furthermore, all RA patients should be monitored for the future development of ILD, especially in patients with risk factors, such as males, smoking, older age, high RF and anti-CCP levels 38 .
Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 in IPF 47, 48 , and reasonable correlation is also seen in RA-ILD 49 . Lee et al. looked at lung biopsy specimens of 18 RA patients with ILD, and found that 10 of 18 patients had the UIP pattern on histology, and 9 of 10 of them had HRCT scans consistent with UIP-like pattern of disease. The other 6 of 18 patients had NSIP pattern of disease on histology and of these, 3 of 6 of them had HRCT findings consistent with a NSIP-like pattern of disease 40 . As a result, surgical lung biopsies are seldom performed to diagnose ILD, unless the HRCT findings are indeterminate.
Other imaging modalities that could be useful in future include lung ultrasounds and 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT). Lung ultrasounds has been shown to correlate well with HRCT in SSc 50 , and Barskova et al. demonstrated in SSc-ILD that patients with ground-glass changes on HRCT had a higher total number of B-lines on lung ultrasound, and concordance with HRCT was 83%. Lung ultrasound had a sensitivity and negative predictive value of 100% in the study, whilst specificity was 55% and positive predictive value was 78% 51 . Following this, a prospective study by Cogliati et al in 39 RA patients, found a sensitivity and specificity of standard lung ultrasound (performed by expert physician) versus HRCT of 92% and 56% respectively, for the detection of ILD 52 . Of interest is that similar results were obtained when a handheld ultrasound device was used by a short-trained physician 52 . The advantages of lung ultrasound as compared to HRCT include its cheaper cost, lack of exposure to ionising radiation, easier availability, repeatability and ease of training an operator.
In a case report, 18F-FDG PET/CT was used to screen for malignancy in a patient with clinically amyopathic dermatomyositis (CADM), and this showed 18F-FDG being distributed peripherally in both lungs, despite the absence of ILD on HRCT and normal arterial blood gases 53 . Despite aggressive immunosuppression, the patient later developed rapidly progressive ILD and died. The authors concluded that 18F-FDG PET/CT may have a role in the detection of early inflammation in ILD.
TREATMENT OF RA-ILD
Two-thirds of patients with RA-ILD have a usual interstitial pneumonia (UIP) pattern of involvement, whilst NSIP accounts for majority of the remaining patients 49 . Whilst RA-ILD patients with an NSIP pattern may benefit from immunosuppressive therapy, it is still unclear if there is benefit in treating patients with a UIP pattern 41 . A retrospective study of 100 patients with a UIP pattern of ILD showed improved survival in patients with an underlying CTD as compared to patients with IPF 54 .
The traditional approach in the treatment of RA-ILD was with glucocorticoids and immunosuppressants such as azathioprine, cyclophosphamide and cyclosporine 55 . However, there is limited efficacy data with these agents due to lack of randomised trials in RA, and treatment options are often extrapolated from other CTD-ILDs, for example SSc. No randomised control trial has been performed for use of cyclophosphamide in RA-ILD, but it has been used with some reported success 55 . In the Scleroderma Lung Study, cyclophosphamide led to a 2.53% (p<0.03) improvement in the forced vital capacity (FVC), 4.09% (p=0.026) improvement in the total lung capacity (TLC) and improvement in the Mahler Transition Dyspnea Index (+1.4 vs -1.5 in placebo; p<0.001) in SSc-ILD patients, 56 and this persisted for up to 24 months 57 .
Newer agents that might have clinical efficacy include mycophenolate mofetil and B cell depleting agents, e.g. rituximab. In a case series, mycophenolate mofetil was used in patients with RA-ILD, with reported improvement in lung function tests and imaging 58 . A meta-analysis of mycophenolate mofetil in SSc-ILD demonstrated a mean improvement of 1.48% [95% confidence interval (CI): −2.77 to 5.72, p=0.49)] of the predicted FVC at 12 months 59 . Although not statistically significant, the authors concluded that mycophenolate mofetil prevented further FVC decline, which was observed in non-responders, and thus had a possible role in disease stabilisation 60, 61 .
After the discovery of CD20+ B cell infiltrates in RA-ILD lungs, rituximab, a B-cell depleting chimeric monoclonal antibody against CD20, has been used for treatment of ILD in RA patients 62 . Rituximab use has resulted in stability of HRCT and pulmonary function findings over 48 weeks in a case series of 14 patients with RA-ILD 63 . Rituximab has also been used successfully in patients with SSc-ILD 64 , antisynthetase syndrome 65 and pulmonary complications of systemic lupus erythematosus (SLE), including lupus pneumonitis 66 , shrinking lung syndrome 67 and pulmonary haemorrhage 66 .
Review
Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 Drugs used to treat arthritis in RA can also cause worsening respiratory failure in patients with RA-ILD. One such example is methotrexate, the American College of Rheumatology (ACR) recommended first-line disease-modifying antirheumatic drug (DMARD) in RA 68 . Methotrexate has been known to cause pneumonitis, with a high mortality rate of about 20% 69 . Patients with reduced pulmonary function at baseline are at increased risk 70 , and the development is most likely within the first 6 months of therapy 69 . Methotrexate has not been shown to accelerate progression of RA-ILD. Another agent implicated is that of leflunomide, which has also been reported to cause pneumonitis 71 . Japanese and Koreans tend to have a higher incidence of pneumonitis with leflunomide compared to the Caucasians 71 , whilst patients with a previous history of methotrexate-induced pneumonitis are also at increased risk of leflunomide-induced pneumonitis 72 . Good response is often achieved after stopping the offending drug.
Tumour necrosis factor (TNF) inhibitors, such as infliximab, etanercept and adalimumab have all been noted to cause onset or exacerbation of ILD after being started 73 . In a retrospective study of 122 cases, 89% of patients had RA. Eighteen of 52 (35%) had no resolution of ILD despite stopping TNF inhibitors, 15 of 52 (29%) eventually died, of which 70% died within 5 weeks after initiation of biologic therapy. Risk factors for death included patients aged >65 years, later onset of ILD, patients who received immunosuppressive drugs more frequently, and those with previous diagnosis of ILD 73 .
Patients with SLE and RA have also developed ILD after starting rituximab treatment 74, 75 . None of the patients were known to have previous ILD. After corticosteroid therapy, all three patients recovered.
FUTURE RESEARCH
Genome-wide association studies performed in RA may allow for genetic markers of susceptibility to RA-ILD to be identified 76, 77 . Proteomic studies of bronchoalveolar lavages have identified differences between various RA-ILD subtypes 78 , and future use of proteomics might hopefully aid in the early diagnosis of RA-ILD, or even predict its future development. It is also exciting to note that Ytterberg et al. has identified similar citrullinated peptides in the bronchial and synovial tissue in RA patients, and this could lead to potentially new therapeutic targets 79 .
CONCLUSION
In summary, ILD is not uncommon in RA, and can be the only manifestation of an underlying rheumatic disease. The presence of anti-CCP and RF, together with features of ILD is useful to establish a diagnosis of RA-ILD. Prognosis is generally poor despite immunosuppressive therapy. It is important to note that drugs used to treat articular disease can also cause or exacerbate underlying ILD.
